Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avanos Medical (AVNS) Cost of Revenue (2016 - 2025)

Avanos Medical's Cost of Revenue history spans 12 years, with the latest figure at $77.5 million for Q3 2024.

  • For Q3 2024, Cost of Revenue rose 2.24% year-over-year to $77.5 million; the TTM value through Sep 2024 reached $303.2 million, up 3.13%, while the annual FY2023 figure was $293.6 million, 1.28% up from the prior year.
  • Cost of Revenue for Q3 2024 was $77.5 million at Avanos Medical, up from $76.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $100.7 million in Q2 2021 and bottomed at $2.8 million in Q4 2021.
  • The 5-year median for Cost of Revenue is $78.3 million (2020), against an average of $77.9 million.
  • The largest annual shift saw Cost of Revenue crashed 97.16% in 2021 before it skyrocketed 2710.71% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $98.5 million in 2020, then plummeted by 97.16% to $2.8 million in 2021, then surged by 2710.71% to $78.7 million in 2022, then fell by 0.51% to $78.3 million in 2023, then dropped by 1.02% to $77.5 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Cost of Revenue are $77.5 million (Q3 2024), $76.1 million (Q2 2024), and $71.3 million (Q1 2024).